Omeros (OMER) Free Cash Flow (2010 - 2026)
Omeros' (OMER) quarterly Free Cash Flow came in at -$14.5 million in Q1 2026, up 59.57% year-on-year from -$9.1 million in Q1 2025, and up 63.59% quarter-over-quarter from -$39.8 million in Q4 2025.
Omeros (OMER) Free Cash Flow (2010 - 2026) Analysis & Trends
Omeros has disclosed Free Cash Flow across 17 years of filings, most recently posting -$14.5 million for Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$14.5 million, up 59.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$94.8 million (up 33.72% YoY), and the FY2025 annual result was -$116.2 million, up 22.02% from the prior year.
- Free Cash Flow came in at -$14.5 million for Q1 2026 at Omeros, up from -$39.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $174.5 million in Q1 2023 to a low of -$46.1 million in Q2 2024.
- The 5-year median for Free Cash Flow is -$29.0 million (2024), against an average of -$17.2 million.
- Across the five-year window, Free Cash Flow jumped 1248.81% in 2023 and sank 123.97% in 2024, its largest moves.
- Omeros' Free Cash Flow stood at -$25.4 million in 2022, then tumbled by 37.6% to -$34.9 million in 2023, then increased by 16.99% to -$29.0 million in 2024, then slumped by 37.36% to -$39.8 million in 2025, then soared by 63.59% to -$14.5 million in 2026.
- The last three Free Cash Flow figures came in at -$14.5 million (Q1 2026), -$39.8 million (Q4 2025), and -$18.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | -14.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.51 Mn |
| Mar 31, 2026 | -14.51 Mn |
| Dec 31, 2025 | -39.84 Mn |
| Dec 31, 2025 | -39.84 Mn |
| Sep 30, 2025 | -18.46 Mn |
| Sep 30, 2025 | -18.46 Mn |
| Jun 30, 2025 | -21.97 Mn |
| Jun 30, 2025 | -21.97 Mn |
| Mar 31, 2025 | -35.88 Mn |
| Mar 31, 2025 | -35.88 Mn |
| Dec 31, 2024 | -29.01 Mn |
| Dec 31, 2024 | -29.01 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Jun 30, 2024 | -46.07 Mn |
| Jun 30, 2024 | -46.07 Mn |
| Mar 31, 2024 | -41.84 Mn |
| Mar 31, 2024 | -41.84 Mn |
| Dec 31, 2023 | -34.94 Mn |
| Dec 31, 2023 | -34.94 Mn |